A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients

Lawson Health Research Institute

Status and phase: Completed; Phase 4

Conditions: Kidney Failure

Treatments: Drug: Dalteparin

Study type: Interventional

Funder types: Other

Identifiers

NCT02607111

107283

Details and patient eligibility

About

This study evaluates the optimal dosage and safety of Dalteparin when used as an anticoagulant for hemodialysis therapies.

Full description

Routine anticoagulation is required during hemodialysis treatments. In North America, the anticoagulant of choice for hemodialysis therapies is unfractionated heparin (UFH), whereas in Western Europe, it is low molecular weight heparin (LMWH). Dalteparin is more commonly used in Canada and has been approved for use in the in-centre thrice-weekly hemodialysis population at a fixed dose of 5000 units. However, there have been no published studies to assess the use of dalteparin in home quotidian and/or nocturnal hemodialysis therapies. Patients on frequent hemodialysis or nocturnal hemodialysis in the home will be converted to Dalteparin from Heparin for 4 weeks to evaluate the optimal dosage and to assess its safety in this population

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently undergoing short-hour daily and nocturnal hemodialysis through the home dialysis program at London Health Sciences Centre.

Exclusion criteria

• Patients with increased bleeding risks
• Currently on full dose anticoagulants
• Active bleeding
• Diabetic retinopathy
• Active cancer receiving treatment within the past 6 months

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

open label

Experimental group

Description:

Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks

Treatment:

Drug: Dalteparin